-
Prof. Wojciech Jurczak on the BRUIN CLL-313 Study and First-Line CLL Treatment
In this video from ASH, Prof. Wojciech Jurczak, consultant hematologist and Head of Department at the Maria Skłodowska-Curie National Research Institute of Oncology, shares key results from the randomized BRUIN…
-
Prof. Othman Al-Sawaf on Fixed-Duration vs Continuous Therapy in CLL
In this video, Prof. Othman Al-Sawaf, hematologist and clinical investigator at the University Hospital Cologne and the German CLL Study Group, shares key findings from a randomized study comparing fixed-duration…
-
ASH China Voice | Deyan Liu / Xiaomei Liu: Allogeneic HSCT Improves Outcomes in SET::CAN–Positive Hematologic Malignancies
From December 6 to 9, 2025, the 67th Annual Meeting of the American Society of Hematology (ASH) was held in Orlando, USA. As the largest and most influential international conference…
-
ASH Global Perspectives | Smart Immune Cell Redirection: SITE Offers a Novel Therapeutic Solution for Multiple Myeloma
Multiple myeloma (MM) is a malignant hematologic tumor originating from plasma cells. Despite significant advances in available therapies, disease relapse and drug resistance remain major barriers to achieving a cure.…
-
2026 CASH Major Preview: Global Hematology Leaders Convene — Internati onal Forum Agenda Revealed
Organized by Institute of Hematology & Blood Disease Hospital, Chinese Academy of Medical Sciences, the 6th Annual Meeting of Chinese Alliance for Society of Hematology (CASH) will be held on Jan. 9-11, 2026, in Tianjin, China. Since its inaugural session in 2021, CASH has become one of the most influential academic events in the field of hematology. Looking back at the previous five sessions, the conference has invited top experts and scholars from both China and abroad, attracting millions of online and onsite participants. It has focused on national strategies,…
-
SABCS Expert Commentary | Professor Jin Feng: Precision Immunotherapy Adds New Evidence in Early Triple-Negative Breast Cancer—Gene Expression–Based Subtyping Predicts Response to Neoadjuvant Immunochemotherapy
At the 2025 San Antonio Breast Cancer Symposium (SABCS 2025), a study entitled “Gene Expression–based Subtyping of Early Triple-Negative Breast Cancer for Prediction of Response to Neoadjuvant Immune-chemotherapy in the NSABP B-59/GBG-96-GeparDouze Trial” (Abstract No. RF3-02) was presented. This study provides an in-depth analysis of the heterogeneity of benefit from immunotherapy in early-stage triple-negative breast…
-
SABCS Hot Commentary | Prof. Jiayi Chen: RadComp Study Releases Comparative Cardiac Outcomes of Proton vs Photon Therapy in Breast Cancer
Study Overview RadComp (NCT02603341) is a multicenter, prospective, randomized phase III trial designed to determine whether the reduction in cardiac radiation dose achieved with proton therapy, compared with photon therapy,…
-
SABCS China Voice | Prof. Mao Xiaoyun: A Nomogram Model Based on Mammographic Imaging to Accurately Predict NAC Efficacy
Study Overview Background Breast cancer remains one of the most common malignancies and a leading cause of cancer-related death among women worldwide, posing a serious threat to women’s health. Neoadjuvant…
Connecting Medical Expertise through Media